

Menopausal Status Affects BMD/CRP Link

BY KERRI WACHTER

DENVER — Menopausal status appears to modify the relationship between inflammation and bone mineral density, on the basis of findings from the Framingham Osteoporosis Study.

Postmenopausal women on estrogen replacement therapy (ERT) with higher levels of C-reactive protein—a measure of systemic inflammation—had greater

bone mineral density (BMD) at the femoral neck than did those in the same group with lower CRP levels, Dr. Robert R. McLean and his coinvestigators reported in a poster at the annual meeting of the American Society for Bone and Mineral Research. In contrast, in premenopausal women, increased CRP levels were associated with a decrease in BMD at the trochanter.

The Framingham Heart Study Off-

spring Cohort enrolled 5,124 children and spouses of the original Framingham cohort. From 1996 to 2001, BMD was measured in 3,035 offspring in the Framingham Osteoporosis Study. Fasting blood samples were collected from 2,095 of them during 1998-2001. C-reactive protein levels were measured after BMD in 72% of participants, with a median time between assessments of 1.4 years.

BMD was measured at the right femoral

neck and trochanter, and at the lumbar spine. Other variables obtained at the time of BMD measurement included age, height, weight, physical activity, smoking status, and use of NSAIDs. In women, menopause status, current ERT use, and years since menopause were recorded. Separate analyses were performed for the 1,291 men, 229 premenopausal women, 497 postmenopausal women using ERT, and 888 postmenopausal women not us-

Obese Women Underscreened For Osteoporosis

WASHINGTON— Obese women are less likely to be screened for osteoporosis than are normal- or overweight women, according to a study of more than 140,000 patients in an integrated health care plan database.

Previous studies showed mixed results on the disparity in preventive health care for obese patients, compared with normal-weight patients, said Kristi Reynolds, Ph.D., and colleagues, of Kaiser Permanente, Pasadena, Calif.

“It is largely unknown whether obesity is associated with the quality of care for osteoporosis, which is both preventable and treatable but is often undiagnosed and untreated,” the researchers said. Physicians may be less inclined to screen obese women for osteoporosis because body weight is associated with higher bone density, they noted.

Data from 146,975 health care provider visits between July 1, 2007, and June 30, 2008, were reviewed.

Average age was 73 years; 35% were normal weight; 35% were overweight; and 19%, 7%, and 4% fell into obesity categories I, II, and III, respectively. Normal weight body mass index was defined as 18.5-24.9 kg/m²; overweight as 25-29.9 kg/m²; obese class I as 30-34.9 kg/m², class II as 35-39.9 kg/m², and class III as 40 kg/m² or higher.

About 67% of the women had undergone bone mineral density testing within 4 years of the study, the criteria by which participants were considered “screened.” Only 52% of women with a BMI of 40 kg/m² or higher were screened, compared with 68% each of the normal BMI women and overweight women, 67% of those with a BMI of 30-34.9 kg/m², and 63% with a BMI of 35-39.9 kg/m².

After adjustment for age, race, and income, the odds ratio of osteoporosis screening for overweight women was 0.99, while the ratios for women in obese classes I, II, and III were 0.90, 0.77, and 0.60, respectively. The findings were presented in a poster at the annual meeting of the Obesity Society.

The results suggest that many overweight and obese women aren’t screened for osteoporosis, said the researchers, who reported having no conflicts of interest.

—Heidi Splete

For your adult patients with type 2 diabetes



Indication and Important Limitations of Use

ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

ONGLYZA has not been studied in combination with insulin.

Important Safety Information

- **Use with Medications Known to Cause Hypoglycemia:** Insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA
- **Macrovascular Outcomes:** There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug

Most common adverse reactions (regardless of investigator assessment of causality) reported in ≥5% of patients treated with ONGLYZA and more commonly than in patients treated with control were upper respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%). When used as add-on combination therapy with a thiazolidinedione, the incidence of peripheral edema for ONGLYZA 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 4.3%, respectively.

ing ERT. Analyses were adjusted for age, height, weight, physical activity, and smoking status, with additional adjustment for NSAID use.

Median CRP levels were higher for postmenopausal women (3.9 mg/L for those on ERT and 2.3 mg/L for those not on ERT) than for men (1.9 mg/L) or for premenopausal women (1.4 mg/L). In all, 74% of men, 62% of premenopausal women, 86% of postmenopausal women on ERT, and 77% of postmenopausal women not on ERT had CRP levels of at least 1 mg/L.

CRP level was not associated with BMD

in men or in postmenopausal women using ERT. However, in those women, there was a significant association between years since menopause and BMD at all three sites. The researchers repeated the analysis for women fewer than 10 years past menopause and those at least 10 years past menopause. "The association of CRP with femoral neck BMD tended to be negative for those less than 10 years past menopause and positive for those at least 10 years past menopause, while there was no significant association at the trochanter or lumbar spine," they wrote.

For postmenopausal women not using

ERT, those with CRP levels of at least 1 mg/L had 2.5% greater BMD at the femoral neck, compared with the lower CRP level group, a significant difference. However, there were no significant associations at the trochanter or lumbar spine. "Contrary to our hypothesis, greater inflammation may be associated with higher BMD among postmenopausal women not using ERT," wrote Dr. McLean, who is a researcher at the Institute for Aging Research, a research affiliate of Harvard Medical School, Boston.

In premenopausal women, CRP level was not associated with BMD at the

femoral neck or the lumbar spine. However, each unit increase in CRP was associated with 0.005 g/cm² lower BMD at the trochanter, which was statistically significant. "Our findings suggest increased systemic inflammation may be a risk factor for lower BMD among premenopausal women, although this was not consistent across bone sites."

Preclinical studies have suggested that proinflammatory cytokines play a role in bone resorption, but the impact on BMD is not clear.

Dr. McLean reported that he has no relevant financial relationships. ■

struggling to gain glycemic control

onglyza[™]
(saxagliptin) 5 mg tablets

Significant reductions in A1C when partnered with key oral antidiabetic agents*

- Onglyza is weight neutral
- Discontinuation of therapy due to adverse events occurred in 3.3% and 1.8% of patients receiving Onglyza and placebo, respectively
- Convenient, once-daily dosing
- Rapidly growing formulary access¹

Drug Interactions: Because ketoconazole, a strong CYP3A4/5 inhibitor, increased saxagliptin exposure, the dose of ONGLYZA should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).

Patients with Renal Impairment: The dose of ONGLYZA is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min). ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis. Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.

Pregnant and Nursing Women: There are no adequate and well-controlled studies in pregnant women. ONGLYZA, like other antidiabetic medications, should be used during pregnancy only if clearly needed. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ONGLYZA is administered to a nursing woman.

Pediatric Patients: Safety and effectiveness of ONGLYZA in pediatric patients have not been established.

*metformin, glyburide, or thiazolidinedione (pioglitazone or rosiglitazone)

Please read the adjacent Brief Summary of the Product Information.

For more information about ONGLYZA visit www.onglyza.com.

Reference: 1. Fingertip Formulary® data as of October 2, 2009. Data on File, October 2009.

 Bristol-Myers Squibb

 AstraZeneca

©2009 Bristol-Myers Squibb 422US09AB12919 10/09
Onglyza™ is a trademark of Bristol-Myers Squibb

292010